Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus Sells 4,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $164.44, for a total value of $657,760.00. Following the completion of the sale, the director now owns 5,704 shares in the company, valued at approximately $937,965.76. The trade was a 41.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Gail Boxer Marcus also recently made the following trade(s):

• On Thursday, May 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The stock was sold at an average price of $151.61, for a total value of $606,440.00.
• On Tuesday, April 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The stock was sold at an average price of $140.78, for a total value of $563,120.00.

Natera Stock Performance

NASDAQ:NTRA opened at $166.76 on Thursday. The firm has a market capitalization of $22.77 billion, a PE ratio of -94.75 and a beta of 1.74. The business’s fifty day moving average price is $153.38 and its 200 day moving average price is $158.62. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same quarter in the prior year, the company posted ($0.56) earnings per share. Natera’s revenue for the quarter was up 36.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on NTRA. UBS Group raised their price objective on Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. BTIG Research reiterated a “buy” rating on shares of Natera in a research note on Friday, February 28th. Robert W. Baird boosted their target price on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, Morgan Stanley boosted their target price on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $184.63.

Institutional Investors Weigh In On Natera

Several hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its position in Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. lifted its position in Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Norges Bank acquired a new stake in Natera in the fourth quarter valued at about $224,040,000. Raymond James Financial Inc. acquired a new stake in Natera in the fourth quarter valued at about $146,419,000. Finally, Vanguard Group Inc. lifted its position in Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock valued at $1,949,697,000 after purchasing an additional 879,463 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.